Technology in The Pharma Supply Chain - A Focus On Anti-Counterfeiting in India

A White Paper by
Frost & Sullivan

50 Years of Growth, Innovation and Leadership
Technology in the Pharma Supply Chain
A Focus on Anti-Counterfeiting in India
2011 Frost & Sullivan
TABLE OF CONTENTS
Introduction and Overview of Indian Pharma Industry ................................. 4
Growing Need of Technology for the Pharma Supply Chain ........................... 5
Technology in Supply Chain ............................................................................ 6
Pharma Supply Chain Challenges ................................................................... 14
Business Case: Technologies and Their Application for the Pharma Supply Chain
........................................................................................................................ 15
The Way Forward ........................................................................................... 17
Annexure ......................................................................................................... 18
F R O S T & S U L L I V A N
INTRODUCTION AND OVERVIEW OF THE INDIAN PHARMA
INDUSTRY
The Indian pharmaceutical industry is 3rd largest in the world in terms of volume
accounting for 10 percent of worlds production and stands 14th in terms of value.
According to data published by the Department of Pharmaceuticals, Ministry of
Chemicals and Fertilizers, the total turnover of Indian Pharma Industry is US$21
billion. Out of this total, domestic formulations market was worth US$8.34 billion
and total APIs market was worth US$3.92 billion. Total Export market was worth
US$8.47 billion. Indian exports go to more than 200 countries around the globe
including the highly regulated markets of US, Europe, Japan and Australia. The
domestic Indian Pharmaceutical market is expected to reach US$ 55 billion in 2020
at a Compound Annual Growth Rate (CAGR) of around 15 percent.
Indian Pharma industry with more than 20,000 registered units is highly fragmented
wi th severe pri ce competi ti on and government pri ce control . There are
approximately 250 large units and more than 8,000 small scale units, which form the
core of the Pharmaceutical industry in India.
Indian Pharma industry has shown remarkable progress in terms of infrastructure
development, technology base creation and its range of products. The industry now
produces bulk drugs belonging to all major therapeutic groups ranging from
complex molecules to simpler manufacturing technologies. Finished Formulations of
various types (tabs, caps, injectables, etc.) of various dosage forms are being
produced in GMP compliant facilities and transported globally.
Indian pharmaceutical companies today are known for their global reach with high
quality generic formulations and world class APIs.
www.frost.com 2011 Frost & Sullivan
4
F R O S T & S U L L I V A N Technology in the Pharma Supply Chain A Focus on Anti-Counterfeiting in India
Pharmaceutical Market India 2010 (in USD Billion)
8.74
8.34
3.92
Exports Domestic Formulations Domestic APIs

2011 Frost & Sullivan www.frost.com
5
GROWING NEED OF TECHNOLOGY FOR PHARMA SUPPLY CHAIN
The success of a global pharmaceutical company can to a large part be attributed
to its successful supply chain. The supply chain ensures drug availability at all
locations across continents, 100 percent product availability at optimum cost by
carrying a huge inventory, which maintains 100 percent fill rate.
The criticality of a seamless supply chain network is often underestimated in the
industry. A recent study has quoted that pharmaceutical companies are trying to cut
down product development time to save costs. For example, a drug manufacturer
who can trim development time by 19 percent can save up to US$ 100 million.
However, a delay in time to market of a drug can cost a company around US$ 1
million a day. So, pharmaceutical companies today are designing the supply chain to
be as responsive as possible to reduce entry time to the market thereby increasing
profit margins.
The Pharma Supply Chain is highly sensitive where anything less than 100 percent
customer service level is unacceptable as it directly impacts patient health and
safety. The solution that many Pharmaceutical industries adopt is to maintain a large
inventory in the supply chain to ensure close to 100 percent fill rate. However, it is
a challenge to ensure 100 percent product availability at an optimal cost across
multiple locations, unless supply chain processes are streamlined towards customer
needs and demands. In this environment, it is no surprise that companies
throughout the industry are hungry for opportunities to improve the efficiency of
their operations, better understand their customers demands, and devise more
creative responses to the marketplaces challenges.
The challenges confronting many Pharma companies in India are:
Managing products in different stages of the lifecycle in an era of multiple new
product launches
Keeping supply chains flexible to align with changes in demand for new drugs,
promotions and disease outbreaks
Maintaining efficiency and effectiveness in growing supply, manufacturing and
subcontractor base
Reaching out to newer domestic and export markets without losing efficiency
Expanding Scope of Supply Chain
Until recently, supply chain was used to track and trace the product up to the
retailer. Product dispensation at retailer and replenishment of the stocks at retailer
levels was part of the sales and marketing function.
6
Scope of Supply Chain, 1990s
With growing importance of supply chains, technology today has an integral role to
play in the system. Companies today are willing to invest in technology to ensure
seamless order to delivery.
Technology in the Supply Chain
As on date technology has been used for two main functions in Supply Chain
Management Analytics and Order to Delivery.
Analytical tools and data-based decision tools such as Enterprise Resource Planning
(ERP) have been implemented by many Pharma companies to fine tune traditional
forecasting and replenishment strategies This analytically driven nimbleness has
allowed leading manufacturers to increase their speed-to-market while improving
their management of working capital critical capabilities in a world where
product lifespans are shrinking year after year. The utility of such an approach for
pharma companies facing tougher generic competition and lengthening R&D
timeframes is obvious.
ERP systems are theoretically based on industry best practices and are intended to
be deployed "as is". ERP vendors do offer customers configuration options that
allow organizations to incorporate their own business rules but often functionality
gaps remain even after the configuration is complete.
Implementing ERP typically requires changing existing business processes. Poor
understanding of needed process changes prior to starting implementation is the
main reason for project failure. It is therefore crucial that organizations thoroughly
analyze business processes before implementation. This analysis can identify

lndusLry's currenL focus ls on lmprovlng producL LraceablllLy and supply chaln securlLy Lo bulld llnks
wlLh cusLomers, dlsLrlbuLlon parLners and all sLakeholders Lo drlve compleLe cusLomer saLlsfacLlon,
accuraLe forecasLlng and Llmely replenlshmenL.

Scope of Supp|y Cha|n, 2010

Manufacturing
&
Packaging

New Product
Development
& Innovation

Carry &
forward
Agent

Distributor
&
Stockiest

Retailer

Manufacturing
&
Packaging

Distributor
&
Stockiest

Retailer

New Product
Development &
Innovation

CFA

Patients /
Consumer
Source: Frost & Sullivan
7
opportunities for process modernization. It also enables an assessment of the
alignment of current processes with those provided by the ERP system.
ERP's scope usually implies significant changes to staff work processes and
practices. Generally, three types of services are available to help implement such
changes: consulting, customization, and support. Implementation time depends on
business size, number of modules, customization, the scope of process changes, and
the readiness of the customer to take ownership for the project. Modular ERP
systems can be implemented in stages. The typical project for a large enterprise
consumes about 14 months and requires around 150 consultants. Small projects can
require months; multinational and other large implementations can take years.
Customization can substantially increase implementation times.
Advantages
The fundamental advantage of ERP is that integrating the myriad processes by which
businesses operate saves time and expense. Decisions can be made more quickly
and with fewer errors. Data becomes visible across the organization. Tasks that
benefit from this integration include:
Sales forecasting, which allows inventory optimization
Order tracking, from acceptance through fulfilment
Matching purchase orders (what was ordered), inventory receipts (what
arrived), and costing (what the vendor invoiced)
Disadvantages
Customization is problematic.
Re-engi neeri ng busi ness processes to fi t the ERP system may damage
competitiveness and/or divert focus from other critical activities
ERP can cost more than less integrated and/or less comprehensive solutions.
High switching costs of support, maintenance and upgrade expenses.
Overcoming resistance to sharing sensitive information between departments
Integration of truly independent businesses can create unnecessary
dependencies.
Extensive training requirements take resources from daily operations.
Anti-Counterfeiting Technology in the Supply Chain
Some of the key applications of technology today have been in anti-counterfeiting
technologies and drug tracking to avoid theft and misuse and ensure timely delivery.
The growing global problem of counterfeit medication poses a crippling risk to
healthcare systems in developing nations. Though authoritative studies are few and
far between, the World Health Organization (WHO) estimates that counterfeit
drug prevalence rates fall between 10 percent and 30 percent in the developing
world, compared to 1 percent or less in industrialized nations. The U.S.-based
Center for Medicines in the Public Interest (CMPI) projects that by 2010, US$ 75
8
billion worth of counterfeit drugs will be sold annually. Fake drug sales are expected
to grow at 13 percent yearly until 2010, a rate significantly higher than the
estimated 7.5 percent annual growth for genuine pharmaceutical commerce. The
Indian Government recently passed a law mandating the use of track-and-trace
barcodes on all drugs meant for export, effective July 2011, following reports that
Chinese counterfeiters were selling fake medicines labelled Made in India in
several African countries.
Developing nations are technologically well behind, primarily due to the fact that
new anti-counterfeit technologies are oft beyond their means. History has shown
that by the time such technologies are affordable, resourceful counterfeiters could
have copied the technology, turning it into a great risk consumers can have a false
sense of security in "protected" counterfeit products. This trend is evidenced in
events that have led to the compromising of microprint, advanced product
packaging, security inks, tableting molds, unique blister packs and even holograms as
fool-proof product security technologies.
There are many technologies adopted by Pharmaceutical companies in India to
track and trace product movement and to check counterfeiting across the supply
chain.
1. Holograms
This category is preferred as a passive technology. The creation of a holographic
image, or hologram, requires some technical knowledge and expertise, though a
recent explosion of companies and low-cost machinery has made this technology
extremely accessible within many sectors of the consumer marketplace. A hologram
typically incorporates an image that appears as an illusory 3-dimensional object
with vivid depth characteristics.
A security hologram is a special reflective type of hologram that is custom-made
for a brand owner. A number of pharmaceutical companies have relied on hologram
application as a means to reduce counterfeiting. There are currently a large number
of hologram suppliers in the global marketplace.
Advantages
Holograms and security seals are generally low priced, easy to apply, and represent
a rapid way of providing a distinguishing feature to a branded product.
Disadvantage
The major disadvantage is this solution is easily replicable by a counterfeiter, and
indeed, there have been numerous instances where genuine security holograms
have been easily and expertly copied or simulated, leading to the contention that
holograms when used alone are less about security and more about sparkle. The
fact that fake holograms used by counterfeiters are not easily distinguishable by the
consumer because many products available in the marketplace have holograms; it is
extremely difficult for consumer to keep up with which products should contain a
particular type of hologram or seal.
9
2. Taggants
This category of anti-counterfeiting solutions is referred to as the active
technologies because they all require an active process during the act of
verification. The application of the various technologies in this category begins with
the insertion or placement of a special marker or device, which is known as a
taggant, into or upon the branded product. In some instances, the taggant can be
placed on the package whereas in others, it can be incorporated directly into the
product itself. In all cases, the subsequent act of authenticating the product requires
a specialized device, reader, or scanner. Each type of taggant can only be detected
by its own specific reader.
Electromagnetic taggants (RFID)
The most commonly used and widely known of the active technologies is radio
frequency identification, or RFID. These taggants rely on radio signals, which are
emitted by an integrated chip or tag. RFID tags can contain significant amounts of
information related to the product and can be placed anywhere within a package
and in fact can be hidden because the emitted radio signals are able to penetrate
through most materials. An RFID reader, which is a specialized instrument that
detects the radio signals, can be used to capture the information emitted by the tag.
The information in turn is then transmitted to a software system that coordinates
all aspects of the RFID operation.
RFID technology, however, has not broken through in terms of its use as a pure anti-
counterfeiting tool in the pharmaceutical industry. RFID industry has undertaken
major efforts to promote this technology as a valid anti-counterfeiting solution.
Advantages
The major advantages of RFID relate to its wireless nature. The tags do not
require line-of-sight or any direct human intervention in order to capture the
digital information. As a result, RFID tags can be hidden in packages so as to

Irost & Su|||van kat|ng:
3 2 1 4 5

10
provide a greater level of security.
RFID tags can be read from a considerable distance, usually many meters,
making it much easier to undertake roaming data capture.
The tags can also be read rapidly in bulk, which is ideal for high-throughout
supply chain tracking.
In some cases, the reader can even write information directly to the tags,
thereby making the RFID technology bi-directional in nature.
Disadvantages
Major disadvantages to the use of RFID as an anti-counterfeiting tool are cost,
reliability, and privacy. The cost of the tags can vary depending on volume but
are generally quite high, which eliminates its use at the product level except for
truly expensive brands. RFID infrastructure development and implementation
would require huge capital investments.
The second factor inhibiting RFID use is reliability, primarily due to reading
errors. Radio waves are easily deflected or impeded by metals and liquids.
Reading error rates reported in various studies vary in the range of 2.5 percent
to 25 percent.
RFID has the potential to capture personal information and thereby represents
a larger problem for society if RFID is widely adopted. One can gather all sorts
of information from any RFID tags that the consumer have on them.
3. Barcode Applications
This category of anti-counterfeiting solutions includes those technologies, which
encode individual branded products in an overt digital manner. The digital
information can appear on a product as a human-readable code (that is,
alphanumeric script) and in terms of a barcode, such as the traditional linear format
or the new generation of 2D barcodes.
A barcode i s an opti cal machi ne-readabl e representati on of data whose
technological origins can be traced back to the 1930s but adopted in mass retail
settings only by the 1970s. Since then, virtually every purchasable item now
contains a barcode. The most commonly used barcodes are the linear or 1D (one-
dimensional) pattern of lines. The coding system that is widely used, the so-called
Universal Product Code (UPC), maps the data contained in the barcode to a
standardized system of information representation.
A new generation of barcodes has been recently developed that provide a 2-
dimensional (2D) way of representing information. The biggest advantage to the 2D
barcode technology is that much greater information can be encoded within a single
barcode. 2D barcodes can contain a mini-database themselves, and therefore
encode much greater information on the product.
3 2 1 4 5
11
Advantages
The 2D barcode technology has now surpassed RFID as the most prominent
track and trace technology for pharmaceutical applications. The European
Federation of Pharmaceutical Industries and Associations (EFPIA) have clearly
come down on the side of 2D barcode.
The cost of 2D barcodes is very low compared to all other technologies. 2D
barcodes offer similar functionalities to RFID at only a fraction of the cost.
Consumer convenience and empowerment will soon be possible because the
emergence of mobile decoders allows consumers to directly interact with the
codes and obtain immediate validation.
Disadvantage
All barcode technologies were originally developed as an inventory and supply chain
management tool and not as anti-counterfeiting applications. As a result, a robust
system of encoding products for authentication and brand protection via a universal
standard was never put in place. The development of 2D barcodes, however, has
now paved the way for their use as an anti-counterfeiting tool. In this regard, two
new technologies have emerged that take advantage of the power of 2D barcodes
and the rapid growth and sophistication of mobile telephony.
Digital Mass Serialization (DMS)
Digital Mass Serialization is the process by which a unique number or code is
assigned to each product sold in the marketplace. It can be generated in a random,
pseudo-random, or sequential manner. Once a batch of codes is generated, it is
transferred to the pharmaceutical company so that they can be printed directly on
the packages during the production process. Alternatively, the code itself can be
pre-printed on a label and then affixed to the product in a manner similar to a
hologram or security seal.
3 2 1 4 5

DMS authent|cat|on process

1. Code Generation 2. Database Entry
6. Consumer purchase
3. Code labeling
4. Shipping
5. Code Scanning at Retailer
7. Consumer authenticate
products through mobile
12
The technology provider generates a code; it is entered into a database that can be
used later at the verification stage. The database itself is managed and maintained
either by the technology provider or the brand owner. The code is printed in
human-readable form as well as a 2D barcode directly on the product or on a label.
The codes themselves can be numeric, alphabetical, or alphanumeric in nature. The
consumer can visually read the printed script code whereas a barcode scanner can
capture the 2D barcode. The emergence of mobile phones with barcode scanners
now allow consumers to even use their mobile phones to directly read the 2D
barcode.
The authentication process involves matching the unique code on a product to
those stored in the database. If the code is present in the database, then it is
deemed to be authentic and so is the product. Several DMS providers have bundled
this technology with their own SMS short-code number. Thus, all the consumer has
to do to authenticate a product is to enter the code in the SMS field, send it to the
short-code number, and then wait for the verification message, which either
provides confirmation of the products authenticity or raises a flag if the code is not
found in the database. The cumbersome act of manually entering the code in an SMS
field can be bypassed by phones containing barcode readers.
Advantage
DMS technology directly empowers consumers to verify a medical product. A well-
designed DMS system, however, will itself flag any failed authentication efforts and
communicate this information to the brand owner, along with the date, time, place,
and mobile number of the consumer who had made the verification attempt.
Disadvantage
The major disadvantage to the DMS technology concerns the operational
characteristics and security of the database containing the serial codes. It is well
known that the larger a database becomes, the greater the time needed to find an
individual item within it. Thus, a database containing hundreds of millions (or even
billions) of codes for a major brand owners annual drug production requirements
becomes problematic in terms of database management and speed optimization. The
brand owner will have to adopt extremely high-end database software systems well-
suited for the purpose, which adds significant cost of the solution.
Digital Mass Encryption (DME)
Digital Mass Encryption (DME) is similar to DMS in all respects except for one
major difference the DME technology does not operate on a database system. As
such, it offers all the advantages of DMS but avoids its major drawbacks
requirement for database management, verification bottleneck at high volumes, and
3 2 1 4 5
13
data security. DME can therefore be considered to be a more advanced and highly
secure version of DMS. The core technology used in DME solution through which
the codes are created and authenticated is fundamentally different from DMS
whereas serialized codes are generally created by random number generators,
encrypted codes are produced by a cryptographic algorithm. The DME algorithm is
also responsible for the decoding process involved in the authentication step.
The encrypted alphanumeric code is unique, unpredictable, and non-repetitive for
eternity. The code can be used not only for authentication (anti-counterfeiting)
purposes but also for hierarchical tracing in a complex supply chain operation. As
such, DME is fully compliant with all regulatory standards, including the emerging e-
pedigree requirements for pharmaceutical products in some countries. In the whole
process a database is not created or required either by technology provider or
Pharma Company.
The DME code itself can be used by anyone with a mobile phone to authenticate
the product at the point of sale, either through SMS or by way of mobile internet.
The reply message sent by the Pharma Company provides verification on the
authenticity of the product, as well as any other information that the brand owner
wishes to transmit to the consumer (for example, expiry date, MRP, usage cautions,
etc). The communication aspects of this technology can also be of significant
importance in the event of a recall since it allows highest degree of granularity, that
is, right now to the consumer level.
The code generated in a DME system is valid for only one authentication. Multiple
authentications attempts of the same code will raise an alert. Multiple failed
authentications of the same code will raise a flag and when confirmation is made
that a particular code has been replicated on duplicate products that code itself
serves as a tag by which the duplicate products can be identified. In such instances,
consumers are directly warned about the duplicate product and they should report
this case along with other pertinent information to the Pharma Company.

DML authent|cat|on process

1. Code Generation
5. Consumers purchase
2. Code labeling
3. Shipping
4. Code Scanning at Retailer
6. Consumers authenticate
products through mobile
14
Pharma Supply Chain Challenges
These passive technologies certainly do allow a consumer to determine that a
hologram or some other visible feature is present. The challenge is to know what
to look for and to be savvy enough to interpret a hidden image or be able to turn
a product just enough to notice the changing colors in an OVI print. This
requirement becomes particularly problematic when a counterfeiter introduces a
fake version of one of these passive technologies, such as a hologram. It is virtually
impossible for ordinary consumers to identify a true hologram from a fake one.
Thus, all of the passive technologies when used alone do not sufficiently empower
consumers in terms of product authentication. The situation changes considerably,
when it comes to the actual ability of an ordinary consumer to use the technology
for authenticating a product. These active technologies are also poor in terms of
consumer empowerment for the simple reason that customers do not carry around
the special readers that are needed for verification. As a result, none of the positive
aspects associated with consumer empowerment are made available to the brand
owner when implementing an active technology. When used as a stand-alone
feature, DMS and DME codes can be verified via SMS on mobile phones, which are
expected to have a market in excess of 850 million subscribers in India alone by
2011. The only technologies that empower consumers in an anti-counterfeiting
requirement are DMS and DME solutions (mass encoding).
3 2 1 4 5
Compar|son of d|fferent techno|og|es w|th respect to 8us|ness Cb[ect|ves

no|ograms kIID 2D 8arcode DMS DML
Achleve compllance wlLh pollcy
AnLl-LhefL/anLl-counLerfelL/anLl-
Lamperlng
lmprove asseL vlslblllLy
lmprove buslness processes
lmprove paLlenL safeLy
lmprove producLlvlLy
lmprove securlLy
reclslon locaLlon
8educe lnvenLory
8educe labour cosLs
CusLomer LmpowermenL
CosL & value
lorenslc & lnLerdlcLlon
SlmpllclLy & AdapLablllLy
Irost & Su|||van kat|ng * 1.S 3.S 3 3.S 4

* 8aLlng ls based on Lhe analysls made on Lhe polnLs menLloned above on Lhe scale of 1 Lo 3 where 1 ls
poor and 3 excellenL.
15
Business Case: Technologies and Their Applications for the Pharma Supply Chain
nonClonableID by Bilcare Technologies
Bilcare Technologies is a division of Bilcare Ltd., focused on creating next-
generation solutions for anti-counterfeiting, security and brand protection across a
wide array of industry sectors. With breakthrough research in nanotechnology,
Bilcare has developed a unique security technology called nonClonableID. It
enables products to be authenticated as they move through the supply chain to the
end consumer, thus protecting brands and preventing misuse.
The technology comprises a nonClonableID fingerprint that can be seamlessly
integrated into any Supply Chain system, providing totally secure and irrefutable
real-time product identification and authentication. It also provides a reliable means
for effective track-n-trace and e-pedigree of products across the supply chain -
from manufacturer to consumer.
The technology innovatively exploits the intrinsic nature of nano- and micro-
structured composites together with their magnetic and optical properties to
provide a foolproof security system. It can significantly enhance security levels with
an impregnable personal access control and identity management system.
nonClonableID employs unique materials-based fingerprints that are prohibitively
difficult to copy. These tamper-evident fingerprints are irreproducible and cannot be
duplicated even by Bilcare.
Features of nonClonableID
Unique fingerprints generated out of randomly distributed micro and nano
particles
Machine-readable fingerprints enable an objective and reliable authentication
process
Real-time authentication through hand-held portable readers
Fingerprints can be integrated with overt systems like barcodes/ RFID tags etc.
and within any existing software/hardware infrastructure
Proprietary scanning device scans the fingerprint and instantly communicates
the encrypted information with a secure server through mobility platforms
such as GPRS, 3G
Complete authentication report on a mobile or computer using robust web
enterprise secured applications and data management at back-end
ID Security
Anti-counterfeiting
Secure Track-n-trace
e-Pedigree
Secure POS Information
16
Solution Offerings
Pharmaceutical
Bi l care offers a comprehensi ve brand securi ty sol uti on wi th mul ti pl e
checkpoints within the pharmaceutical supply chain to identify counterfeits. It
can al so address unauthori zed acti vi ti es of pl ayers wi thi n the l egal
pharmaceutical supply chain. Bilcares solution ensures enhanced brand
recognition in the marketplace, brand loyalty from patients and an eco-system
that discourages counterfeiters.
Medical Compliance
Patient Compliance
Bilcares solution ensures proper dispensation of medication and compliance
with the medication regimen. It also creates the capability to monitor
compliance on a real-time basis.
Clinicom Solution
nonClonableID enhances the positive outcome of clinical trials by verifying
the authenticity of origin and pedigree of a drug in the clinical trial phase
through its advanced Clinicom solution.
Agrochemicals
Bilcare offers a holistic solution to combat Agrochemical counterfeiting through
the implementation of its unique nonClonableID technology. Integrated as
unit-level tags, nonClonableID enables identification, authentication and
brand protecti on. Wi th i ncreased vi si bi l i ty across the supply chai n,
consignments can be tracked down to individual Stock Keeping Units.
Sproxil Inc.s Mobile Product Authentication (MPA) technology
India ships drugs to over 150 countries and is a key supplier to emerging markets
where counterfeiting is often an issue. Brand and product pirates in Indian markets
pose a significant risk to legitimate Indian manufacturers, leading to brand
degradation, decrease in sales and consumer purchasing apprehension.
Sproxil Inc, a global brand protection company with its novel Mobile Product
Authentication (MPA) technology, would help to restrict proliferation of counterfeit
medicines in developing markets. The company has received a fund infusion of $1.8
million from Acumen to kick start the technology in India and East African countries
of Kenya, Tanzania and Uganda in East Africa.
MPA technology is the worlds only patented consumer SMS (Short Message
Service) verification service via cell phone. It enables consumers to verify the
authenticity of a pharmaceutical product by sending the unique code on the drug as
a free text. Sproxil has ensured smooth compliance of MPA with Indian pharma
companies adhering to the Indian regulatory requirements. The company has
already signed up two major pharma companies in India at Mumbai and Bangalore
who will use MPA to prevent drug counterfeiting.
17
The technology, which will drive economies-of-scale, would benefit consumers,
government and the pharma companies. It will help the consumer who purchases
the drugs from the pharmacy counter to get a customized text message on his cell
response indicating that the product is not a fake and with health literacy tips for
the condition for which the medicine is prescribed.
The US-based company, set up in 2009, launched MPA in February 2010 with Merck
Serono as a pilot project for its anti diabetic product Glycophage. It has established
the first national mobile-based anti-counterfeit service in Africa and sold millions of
anti-counterfeit labels. The anti-counterfeiting strategy is now adopted by
GlaxoSmithKline for its drug Ampiclox and Johnson & Johnson Janssen for its derma
cream Cilag (Nizoral).
The Way Forward
The new generation of low-cost technologies, combined with emerging software
solutions, has the potential to deliver unprecedented value for Supply Chain
Management. Healthcare and other allied life sciences sectors are expected to
follow the trends observed in the pharmaceutical industry. The reason is that these
industries are driven by the need for anti-counterfeiting measures and patient
safety enhancements, and not just economics. This is good for the Healthcare
industry as it will drive scale, which in turn will drive down costs for all Healthcare
constituents. The need of an hour is affordable technology solution that helps
improve overall process efficiencies in the Healthcare Industry which in turn shall
enable a reduction in delivery costs to the end user, which in this case is the
patient.
ABOUT FROST & SULLIVAN
Frost & Sullivan enables clients to accelerate growth and achieve best-in-class positions in growth,
innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's
Growth Team with disciplined research and best-practice models to drive the generation, evaluation,
and implementation of powerful growth strategies. We leverage 50 years of experience in partnering
with Global 1000 companies, emerging businesses and the investment community from over 40 offices
on six continents.
DISCLAIMER
These pages contain general information only and do not address any particular circumstances or requirements. Frost & Sullivan does not give
any warranties, representations or undertakings (expressed or implied) about the content of this document; including, without limitation any as
to quality or fitness for a particular purpose or any that the information provided is accurate, complete or correct. In these respects, you must
not place any reliance on any information provided by this document for research, analysis, marketing or any other purposes.
This document may contain certain links that lead to websites operated by third parties over which Frost & Sullivan has no control. Such links
are provided for your convenience only and do not imply any endorsement of the material on such websites or any association with their
operators. Frost & Sullivan is not responsible or liable for their contents.
COPYRIGHT NOTICE
The contents of these pages are copyright Frost & Sullivan Limited. All rights reserved.
Except with the prior written permission of Frost & Sullivan, you may not (whether directly or indirectly) create a database in an electronic or
other form by downloading and storing all or any part of the content of this document.
No part of this document may be copied or otherwise incorporated into, transmitted to, or stored in any other website, electronic retrieval
system, publication or other work in any form (whether hard copy, electronic or otherwise) without the prior written permission of Frost &
Sullivan.
Auckland
Bangkok
Beijing
Bengaluru
Bogot
Buenos Aires
Cape Town
Chennai
Colombo
Delhi / NCR
Dhaka
Dubai
Frankfurt
Hong Kong
Istanbul
Jakarta
Kolkata
Kuala Lumpur
London
Mexico City
Milan
Moscow
Mumbai
Manhattan
Oxford
Paris
Rockville Centre
San Antonio
So Paulo
Seoul
Shanghai
Silicon Valley
Singapore
Sophia Antipolis
Sydney
Taipei
Tel Aviv
Tokyo
Toronto
Warsaw
Washington, DC
For information regarding permission, write to:
Frost & Sullivan India Pvt Ltd
Tower 6, 4th Floor, Solitaire Corporate Park
Chakala, Andheri (East), Mumbai - 400 093
Maharashtra, India
Phone: + 91 - 22 6160 6666
Fax: + 91 - 22 28324713
Email: anishc@frost.com

Technology in The Pharma Supply Chain - A Focus On Anti-Counterfeiting in India

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Technology in The Pharma Supply Chain - A Focus On Anti-Counterfeiting in India

Uploaded by

Copyright:

Available Formats

A White Paper by

Frost & Sullivan

You might also like